Sandoz won FDA approval for its biosimilar version of Enbrel.
Sandoz, a Novartis division that produces biosimilars, announced on August 30, 2016 that FDA approved Erelzi (etanercept-szzs), a biosimilar to etanercept, for all indications included in the reference product label, including rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. Erelzi is the second biosimilar from Sandoz approved in the United States. The FDA approval follows a unanimous vote (20-0) by the FDA's Arthritis Advisory Committee (AAC) in July to recommend use in all indications of the reference product. In briefing documents submitted before the panel, FDA officials said the drug had no clinically meaningful differences from its reference product.
The approval is based on a package of analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. An application for Sandoz biosimilar etanercept has been accepted by the European Medicines Agency and is currently undergoing review. In a statement, Sandoz says it plans to launch five biosimilars of major oncology and immunology biologics by 2020. The company plans to submit 11 filings over a three-year period, and has already submitted six.
Source: Novartis
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.